Yang et al. identified that tRF-315 derived from tRNALys may protect prostate cancer cells from mitochondrion-dependent apoptosis induced by cisplatin through targeting genes including GADD45A, suggesting that tRF-315 may serve as a therapeutic target or predictive indicator for prostate cancer treatment [192]. Here, GADD45A is linked to prostate carcinoma.